[Action of SERM and SAS (tibolone) on breast tissue]

Contracept Fertil Sex. 1999 May;27(5):368-75.
[Article in French]

Abstract

SERMs are developed in HRT in order to provide the beneficial effects of estradiol on bone and the cardiovascular system. SERMs are antiestrogens and their properties depend upon the pharmacological class they belong to. Tibolone is a progestin with mixed properties. Our studies on breast cells in vitro demonstrated that it behaves as a progestin in these cells. The clinical data obtained with these various therapies on breast are presented.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast / drug effects*
  • Breast Neoplasms / drug therapy
  • Estrogen Antagonists / therapeutic use*
  • Female
  • Humans
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Norpregnenes / therapeutic use*
  • Receptors, Estrogen / agonists*
  • Receptors, Estrogen / antagonists & inhibitors*
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Estrogen Antagonists
  • Norpregnenes
  • Receptors, Estrogen
  • Tamoxifen
  • tibolone